Open AccessWild-type p53-induced phosphatase sensitizes acute myeloid leukemia cells to conventional chemotherapy
Author(s) -
Vasily Golotin,
Ekaterina Belotserkovskaya,
Larisa Girshova,
Alexey Petukhov,
Andrey Zaritsky,
Oleg N. Demidov
Publication year - 2021
Publication title -
biological communications
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.195
H-Index - 5
eISSN - 2587-5779
pISSN - 2542-2154
DOI - 10.21638/spbu03.2021.308
Subject(s) - myeloid leukemia , cancer research , phosphatase , chemotherapy , leukemia , wild type , cytotoxicity , biology , in vitro , chemistry , pharmacology , immunology , enzyme , biochemistry , gene , genetics , mutant
Recently wild-type p53-induced phosphatase was implicated in the pathogenesis of acute myeloid leukemia (AML) and “pre-leukemia” myeloproliferative conditions. Here we decided to check how the strategy directed to phosphatase inhibition affected sensitivity to conventional chemotherapy. All experiments were conducted on AML cell lines cultivated in vitro. The levels of wild-type p53-induced phosphatase vary in different AML cell lines. The chemical compound GSK2830371 reduced levels of phosphatase and diminished its activity. GSK2830371 did not significantly change the cell cycle distribution of AML cells when used alone or in combination with the anti-cancer chemotherapeutic drug Cytosar but increased caspase-dependent PARP1 cleavage. In contrast with previous studies, we did not observe the negative effect of phosphatase activity inhibition and depletion on cells when a chemical inhibitor was used as monotherapy. Using a combination of GSK2830371 with Cytosar we were able to reduce the threshold of chemotherapy-dependent cytotoxicity and more efficiently eliminate leukemic cells. We propose considering inhibition of wild-type p53-induced phosphatase as a prospective strategy in improving anti-AML therapy.